Here are four insights:
1. K2M has positioned itself as a strong competitor in the complex spinal deformity market.
2. The company has disrupted the scoliosis market, offering products that are less invasive and more convenient.
3. In 2015, K2M received 15 FDA approvals and launched numerous new products including Cascade, Everest, Mesa 2 and Capri corpectomy cages.
4. Although the company’s shares seem undervalued, K2M is small and the new products may drive growth in 2016.
More articles on devices:
RTI Surgical launches Streamline TL Spinal Fixation System with new capabilities — 4 highlights
Bodycad introduces Bodycad OnCall for personalized restoration evaluation process — 5 takeaways
Emerging medical device companies find help in AcceLinx’s new program — 4 takeaways
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
